Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Reduced glutathione · 1 trial · 1 indication
Skin reaction scale along with evaluation by radiation oncologist at weekly intervals from start of radiation therapy until completion of radiation.
| Arm | Type | Description |
|---|---|---|
| Group A, RayGel Topical Cream | ACTIVE_COMPARATOR | RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments. |
| Arm B Placebo Topical Cream | PLACEBO_COMPARATOR | Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments. |
| Name | Type | Description |
|---|---|---|
| Reduced glutathione | DRUG | - |
Inclusion Criteria: 1\. Breast Cancer * Radiation Exclusion Criteria: 1. Post Mastectomy 2. Previous irradiation of the same breast 3. Pregnacy 4. Younger than 18 years of age
Top 20 of 92 competitors
Reduced glutathione is an investigational small molecule being studied for use in breast cancer. It is being evaluated as a skin care intervention during external beam radiation therapy for breast cancer patients. The drug is currently in Phase 2 clinical development and is not yet approved by the FDA.
Reduced glutathione is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 2 clinical trials for use in breast cancer patients undergoing radiation therapy.
Reduced glutathione is in Phase 2 clinical development. It is an investigational drug being studied for breast cancer, specifically as a skin care option during external beam radiation. The drug has completed one Phase 2 trial and is not yet approved by the FDA.
Reduced glutathione has been studied in one completed Phase 2 clinical trial, identified as NCT00266331. The trial, titled 'RayGel-An Alternative for Skin Care During External Beam Radiation', enrolled 150 female participants aged 18 years and older in the United States. The trial was randomized, double-blind, and placebo-controlled.
Reduced glutathione is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for use in breast cancer. The drug has completed one Phase 2 trial, but it remains under investigation and has not received regulatory approval.